中华肝脏病杂志2024,Vol.32Issue(4) :289-294.DOI:10.3760/cma.j.cn501113-20240227-00097

肝病新药临床研发的现状和挑战

Current status and challenges of clinical research and development of new drugs for liver diseases

沈镇扬 蔡晓波 陆伦根
中华肝脏病杂志2024,Vol.32Issue(4) :289-294.DOI:10.3760/cma.j.cn501113-20240227-00097

肝病新药临床研发的现状和挑战

Current status and challenges of clinical research and development of new drugs for liver diseases

沈镇扬 1蔡晓波 1陆伦根1
扫码查看

作者信息

  • 1. 上海交通大学医学院附属第一人民医院消化内科,上海 200080
  • 折叠

摘要

肝病在全球是一个严重的公共卫生问题,影响人类的健康,但是目前针对肝病治疗,尤其是新药治疗仍有许多未满足的需求.目前尚无根除乙型肝炎病毒的治疗方法,也无肝纤维化和肝衰竭等的治疗药物,肝癌的化疗和靶向及免疫治疗还不尽如人意.现就目前针对肝病的新药研发的现状与面临的挑战进行概述.

Abstract

Liver disease is a serious public health problem worldwide,affecting human health.However,there are still many unmet needs for the treatment of liver disease,especially with new therapeutic drugs.At present,there is no treatment method to eradicate the hepatitis B virus,nor are there therapeutic drugs for liver fibrosis,liver failure,and others.Chemotherapy and targeted immunotherapy are still unsatisfactory for liver cancer.This article provides an overview of the current status and challenges that arise in new drug research and development for liver diseases.

关键词

疾病,肝脏/新药/研发和应用

Key words

Liver disease/New drugs/Research and development

引用本文复制引用

出版年

2024
中华肝脏病杂志
中华医学会

中华肝脏病杂志

CSTPCDCSCD北大核心
影响因子:1.625
ISSN:1007-3418
参考文献量33
段落导航相关论文